Results of Operation and Financial Condition On August 6, 2026, we issu ed a press release to report our financial results for the quarter ended June 30, 2026. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1. The information in this Form 8-K and the Exhibit attached to this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section…

Results of Operation and Financial Condition On May 7, 2026, we issu ed a press release to report our financial results for the quarter ended March 31, 2026. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1. The information in this Form 8-K and the Exhibit attached to this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section,…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The information contained in

Entry into a Material Definitive Agreement Loan and Security Agreement On May 4, 2026, Lexicon Pharmaceuticals, Inc. (“ Lexicon ”) and its subsidiaries entered into a loan and security agreement with Hercules Capital, Inc. and certain of its affiliates (“ Hercules ”) that provides up to $100 million in borrowing capacity (the “ Hercules Term Loans ”) available in three tranches, each maturing in May 2030. Monthly interest-only payments are due during an initial 18-month period, which may be e…

The issuance of the warrants discussed above and the underlying shares of common stock issuable upon exercise of the warrants have not been and will not be registered under the Securities Act of 1933, as amended (the “ Securities Act ”). The issuance of the warrants was made in reliance on the exemption from the registration requirements of the Securities Act provided by Section 4(a)(2) thereof. Any shares of common stock issuable upon exercise of the warrants will be issued in reliance on th…

Unregistered Sale of Equity Securities On April 30, 2026, each outstanding share of our Series B Convertible Preferred Stock, par value $0.01 per share (the “Preferred Stock”), was converted (the “conversion”) into 50 shares of our common stock, par value $0.001 per share (the “Common Stock”). 408,434.7 shares of Preferred Stock were outstanding immediately prior to the conversion, and 20,421,735 shares of Common Stock were issued as a result of the conversion. The Preferred Stock was sold in…

The filing pertains to the approval of equity incentive plans and does not involve any changes in management or executive departures.

Results of Operation and Financial Condition On March 5, 2026, we issu ed a press release to report our financial results for the quarter and year ended December 31, 2025. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1. The information in this Form 8-K and the Exhibit attached to this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of…

Material Modification to Rights of Security Holders To the extent required, the information regarding the Certificate of Designations (as defined below) set forth in

Entry into a Material Definitive Agreement Underwriting Agreement On January 29, 2026, Lexicon Pharmaceuticals, Inc. (the “ Company ”) entered into an Underwriting Agreement (the “ Underwriting Agreement ”) with Jefferies LLC (“ Jefferies ”) and Piper Sandler & Co. (“ Piper Sandler ”), as representatives of the several underwriters named therein (the “ Underwriters ”), relating to a public offering (the “ Public Offering ”) of 32,000,000 shares (the “ Shares ”) of the Company’s common stock,…

by reference. A total of 23,100,000 shares of Common Stock are issuable upon conversion of the maximum issuable number of shares Preferred Stock pursuant to the Preferred Private Placement. The Concurrent Private Placement, the Preferred Private Placement and the issuance of any Common Stock upon conversion of the Preferred Stock will be taken in reliance upon the exemption from the registration requirements of the Securities Act provided by Section 4(a)(2) thereof.

Regulation FD Disclosure. On January 29, 2026, Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), issued a press release (the “ Launch Press Release ”) announcing the launch of its underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001 (the “ Common Stock ”) and its intention to sell shares of its Common Stock in a concurrent private placement to an affiliate of Invus, L.P., the Company’s large…

Results of Operations and Financial Disclosure The Company previously announced that it ended 2025 with cash, investments and restricted cash of $125.2 million (unaudited), sufficient to support planned operations into 2027, and that it achieved a $10 million milestone in January pursuant to its licensing agreement with Novo Nordisk, with the potential for up to an additional $20 million in milestone payments throughout 2026 (although there is no certainty such milestones will be reached on t…

Other Events. On November 6, 2025, Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “Company”), in connection with its previously announced Open Market Sale Agreement SM , dated December 29, 2023 (the “Agreement”), with Jefferies LLC, as sales agent, pursuant to which the Company may offer and sell, from time to time, through Jefferies, shares of its common stock, par value $0.001, having an aggregate sales price of up to $75,000,000 (the “Shares”), filed a prospectus supplement (th…

Other Events. On November 6, 2025, Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “Company”), in connection with its previously announced Open Market Sale Agreement SM , dated December 29, 2023 (the “Agreement”), with Jefferies LLC, as sales agent, pursuant to which the Company may offer and sell, from time to time, through Jefferies, shares of its common stock, par value $0.001, having an aggregate sales price of up to $75,000,000 (the “Shares”), filed a prospectus supplement to…

Results of Operation and Financial Condition On November 6, 2025, we issu ed a press release to report our financial results for the quarter ended September 30, 2025. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1. The information in this Form 8-K and the Exhibit attached to this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that…

Results of Operation and Financial Condition On August 6, 2025, we issu ed a press release to report our financial results for the quarter ended June 30, 2025. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1. The information in this Form 8-K and the Exhibit attached to this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section…

Entry into a Definitive Material Agreement On June 2, 2025, our stockholders approved (a) an amendment to our 2017 Equity Incentive Plan increasing the total number of shares of our common stock that may be issued pursuant to stock awards granted under the plan from 55,000,000 to 75,000,000, all of which may be granted as stock options, and (b) an amendment to our 2017 Non-Employee Directors’ Equity Incentive Plan increasing the total number of shares of our common stock that may be issued pu…

Results of Operation and Financial Condition On May 13, 2025, we issu ed a press release to report our financial results for the quarter ended March 31, 2025. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1. The information in this Form 8-K and the Exhibit attached to this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section,…

Entry into a Material Definitive Agreement. Exclusive License Agreement with Novo Nordisk On March 27, 2025, we entered into an Exclusive License Agreement (the “ Agreement ”) with Novo Nordisk A/S (“ Novo Nordisk ”) for the worldwide development, manufacture and commercialization of LX9851, our preclinical drug candidate for obesity and associated cardiometabolic disorders. Under the Agreement, we granted Novo Nordisk an exclusive, worldwide, royalty-bearing right and license under our paten…

Results of Operation and Financial Condition On March 6, 2025, we issu ed a press release to report our financial results for the quarter ended December 31, 2024. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1. The information in this Form 8-K and the Exhibit attached to this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that sect…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On January 3, 2025, we received a letter (the “Notice”) from the Listing Qualifications staff of The NASDAQ Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of our common stock for the last 31 consecutive business days, we no longer meet the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5450(a)(1). In accordance wit…

CFO — Scott M. Coiante: Mr. Coiante was appointed as the new CFO, replacing Kristen L. Alexander.

Costs Associated with Exit or Disposal Activities. Following our receipt of a "deficiencies preclude discussion" letter from the U.S. Food and Drug Administration regarding our New Drug Application for ZYNQUISTA ™ (sotagliflozin) as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease, on November 22, 2024 we determined to eliminate our commercial operations and rationalize resources across all functions in order to preserve cash and foc…

Director — Robert J. Lefkowitz, M.D.: Dr. Robert J. Lefkowitz retired from the board of directors, and Ivan H. Cheung was elected to succeed him.